eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2019
vol. 36
 
Share:
Send email
Share:
abstract:
Original paper

Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit

Ewa Cichocka-Jarosz
1
,
Marcin Stobiecki
2
,
Marita Nittner-Marszalska
3
,
Urszula Jedynak-Wąsowicz
1
,
Piotr Brzyski
4
,
Immunotherapy Section of the Polish Society of Allergology Working Group (PTA)

  1. Department of Paediatrics, Jagiellonian University Medical College, Krakow, Poland
  2. Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland
  3. Department of Internal Disease and Allergology, Medical University of Wroclaw, Wroclaw, Poland
  4. “Dziupla” Statistical Analysis, Krakow, Poland
Adv Dermatol Allergol 2019; XXXVI (3): 346-353
DOI: https://doi.org/10.5114/ada.2019.85642
Online publish date: 2019/06/19
View full text Get citation
 
Introduction
Venom immunotherapy treatment (VIT) is the only causal treatment of hymenoptera venom anaphylaxis, which aims to provide long-lasting immunoprotection against severe reactions to subsequent stings.

Aim
To reassess the compliance of VIT procedures in the Polish allergy centres with the European guidelines.

Material and methods
A structured questionnaire survey conducted in all 33 VIT-centres. The response rate was 94%.

Results
The ultrarush initial protocol was the most common protocol (71%, n = 22), usually lasting for 3.5 h (50%, n = 7). The most frequent (36%, n = 11) time interval from the initial to the first maintenance dose (MD) was 14 days, ranging from 7 to 35 days. All centres used an MD of 100 µg. The most frequent time interval between subsequent MDs was 4 weeks (58%, n = 18). Five years’ of VIT was declared by 71% (n = 22). Before the termination of treatment, more than half of the centres (58%, n = 18) performed sIgE and almost half (42%, n = 13) performed skin tests. To confirm VIT efficacy, few centres (26%, n = 8) conducted the sting challenge. About half of centres provided the patients with an adrenalin auto-injector both at the time of initial diagnostics and at the end of treatment. More than half (55%, n = 17) used antihistamines in all patients. Almost half (45%, n = 14) declared to stop treatment with -blockers and almost one fourth (23%, n = 7) discontinued angiotensin-converting-enzyme inhibitors.

Conclusions
In the most important procedures, there is a very high compliance with the guidelines. In the areas where the guidelines are not precise, we observed a large spread of results.

keywords:

venom allergy, immunotherapy, national survey
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.